Page last updated: 2024-12-05

pinacidil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pinacidil is a potent and selective opener of ATP-sensitive potassium (KATP) channels. It has been shown to have a variety of pharmacological effects, including vasodilation, antihypertensive, antidiabetic, and cardioprotective effects. Pinacidil is synthesized through a multi-step process involving the reaction of 4-chloro-3-nitrobenzoic acid with 2-amino-4-methylthiazole. The resulting compound is then reacted with a variety of substituted anilines to produce a series of pinacidil analogs. The KATP channel is a crucial regulator of cellular function, and its opening can lead to a number of beneficial effects. Pinacidil has been studied extensively for its potential therapeutic benefits in a number of diseases, including hypertension, diabetes, and heart failure. Research on pinacidil is ongoing to investigate its efficacy and safety in humans and to explore its potential for developing novel therapeutic agents.'

Pinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID21846
CHEMBL ID545131
SCHEMBL ID635393
MeSH IDM0029848
PubMed CID4826
CHEMBL ID1159
CHEBI ID91706
SCHEMBL ID65787
SCHEMBL ID9260276
MeSH IDM0029848
PubMed CID55329
CHEMBL ID1200338
CHEBI ID34923
SCHEMBL ID65786
SCHEMBL ID8478960
MeSH IDM0029848

Synonyms (294)

Synonym
5633-14-7
D03087
benzetimide hydrochloride (usan)
dioxatrine (tn)
benzetimide hydrochloride
r 4929
einecs 227-072-8
spasmentral
3-phenyl-1'-(phenylmethyl)(3,4'-bipiperidine)-2,6-dione monohydrochloride
dioxatrine
dl-1-benzyl-4-(2,6-dioxo-3-phenyl-3-piperidyl)piperidine hydrochloride
mcn-jr 4929
(3,4'-bipiperidine)-2,6-dione, 3-phenyl-1'-(phenylmethyl)-, monohydrochloride
glutarimide, 2-(1-benzyl-4-piperidyl)-2-phenyl-, hydrochloride
mcn-jr4929
2-(1-benzyl-4-piperidyl)-2-phenylglutarimide monohydrochloride
benzetimide hydrochloride [usan]
dl-2-(1-benzyl-4-piperidyl)-2-phenylglutarimide hydrochloride
smr000718634
MLS001201802
mcn-jr-4929-11
janssen r 4929
benzetimide hcl
janssen r 492
janssen-r-492
CHEMBL545131
v6erx20phb ,
unii-v6erx20phb
benzetimide hydrochloride [mi]
SCHEMBL635393
R4929 ,
HY-B1547A
benzetimide (hydrochloride)
CS-5308
2-[1-benzyl-4-piperidyl]-2-phenylglutarimide
AC-28141
FT-0696859
AKOS025402010
1'-benzyl-3-phenyl-3,4'-bipiperidine-2,6-dione hydrochloride
BCP11991
benzetimide hcl; r4929 hcl; r 4929 hcl; r-4929 hcl
BCP28424
Q27291593
F85330
MS-26755
3-(1-benzylpiperidin-4-yl)-3-phenylpiperidine-2,6-dione,hydrochloride
5633-14-7 (hcl)
3-(1-benzylpiperidin-4-yl)-3-phenylpiperidine-2,6-dione;hydrochloride
DTXSID101036320
CBIOL_001878
MLS002154248
HMS3267P10
AB00052442-04
BRD-A58207013-001-01-2
BRD-A43882281-001-06-4
3-cyano-2-(3,3-dimethylbutan-2-yl)-1-pyridin-4-ylguanidine
gtpl2412
DIVK1C_006855
s-1230 ,
smr000058360
p-1134
MLS000069377 ,
BSPBIO_001461
EU-0101037
SPECTRUM_000387
BSPBIO_002360
IDI1_033931
2-cyano-3-(4-pyridinyl)-1-(1,2,2-trimethylpropyl)guanidine
guanidine, n-cyano-n'-4-pyridinyl-n''-(1,2,2-trimethylpropyl)-, monohydrate
(r,s)-pinacidil
einecs 262-294-9
pinacidilum [inn-latin]
s 1230
pinacidil anhydrous
n-cyano-n'-4-pyridinyl-n''-(1,2,2-trimethylpropyl)guanidine
p 1134
(+-)-pinacidil
guanidine, n-cyano-n'-4-pyridinyl-n''-(1,2,2-trimethylpropyl)-
PRESTWICK_396
BIO2_000181
BIO1_000653
BIO1_001142
BIO1_000164
BIO2_000661
PRESTWICK2_000246
LOPAC0_001037
BPBIO1_000036
BCBCMAP01_000050
BSPBIO_000032
PRESTWICK3_000246
SPECTRUM5_001372
pinacidil
NCGC00095199-01
NCGC00025188-04
NCGC00095199-02
NCGC00025188-05
(+-)-2-cyano-1-(4-pyridyl)-3-(1,2,2-trimethylpropyl)guanidine monohydrate
guanidine, n''-cyano-n-4-pyridinyl-n'-(1,2,2-trimethylpropylmonohydrate), (+-)-
guanidine, n''-cyano-n-4-pyridinyl-n'-(1,2,2-trimethylpropyl)-, monohydrate, (+-)-
KBIOSS_000867
KBIO3_000362
KBIO2_000181
KBIO1_001799
KBIO2_000867
KBIOGR_000181
KBIO2_006003
KBIO3_000361
KBIOSS_000181
KBIO2_005317
KBIO2_002749
KBIO2_003435
PRESTWICK1_000246
SPECPLUS_000759
SPBIO_002251
PRESTWICK0_000246
SPBIO_001818
SPECTRUM2_001739
SPECTRUM2300270
NCGC00025188-07
NCGC00025188-02
NCGC00095199-04
NCGC00025188-03
NCGC00025188-06
NCGC00095199-03
anhydrous, pinacidil
( inverted question mark)-n-cyano-n'-4-pyridinyl-n''-(1,2,2-trimethylpropyl)-guanidine
HMS2094G21
P-154 ,
HMS2089C19
HMS1989J03
bdbm50240750
n''''-cyano-n-pyridin-4-yl-n''-(1,2,2-trimethylpropyl)guanidine
4n-cyanoimino[1,2,2-trimethyl-(1r)-propylamino]methyl-4-pyridinamine
()-n-cyano-n''-4-pyridinyl-n''''-(1,2,2-trimethylpropyl)guanidine
n-pyridin-4-yl-n''-(1,2,2-trimethyl-propyl)-cyanoguanidine (pinacidil)
n''''-cyano-n-pyridin-4-yl-n''-(1,2,2-trimethylpropyl)guanidine (pinacidil)
(+/-)-pinacidil
n''''-cyano-n-pyridin-4-yl-n''-[(1s)-1,2,2-trimethylpropyl]guanidine
4n-cyanoimino[1,2,2-trimethyl-(1s)-propylamino]methyl-4-pyridinamine
4n-cyanoimino(1,2,2-trimethylpropylamino)methyl-4-pyridinamine(pinacidil)
n''''-cyano-n-pyridin-4-yl-n''-(1,2,2-trimethylpropyl)guanidine ((+)-pinacidil)
n''''-cyano-n-pyridin-4-yl-n''-[(1r)-1,2,2-trimethylpropyl]guanidine
NCGC00025188-08
1-cyano-2-(3,3-dimethylbutan-2-yl)-3-pyridin-4-ylguanidine
nsc-759588
CHEMBL1159 ,
HMS1791J03
HMS1361J03
HMS1568B14
HMS1922L10
AKOS001637331
NCGC00188958-01
NCGC00247667-01
HMS3263O15
HMS2095B14
unii-7b0zzh8p2w
nsc 759588
nsc759588
pharmakon1600-02300270
CCG-205115
cas_85371-64-8
nsc_4826
bdbm86245
HMS2234F10
CCG-39493
NCGC00015787-04
NCGC00015787-03
NCGC00015787-05
NCGC00015787-06
NCGC00015787-02
pinacidil [inn]
unii-bb4ugo5k0d
pinacidilum
bb4ugo5k0d ,
60560-33-0
FT-0630932
LP01037
HMS3371H14
(+/-)-2-cyano-1-(4-pyridinyl)-3-(1,2,2-trimethylpropyl)guanidine monohydrate
CCG-222341
SCHEMBL65787
guanidine, n''-cyano-n-4-pyridinyl-n'-(1,2,2-trimethylpropyl)-,(+/-)-
pinacidil [mi]
1-(3,3-dimethylbutan-2-yl)-2-cyano-3-(pyridin-4-yl)guanidine
113563-69-2
pinacidil [who-dd]
tox21_501037
NCGC00261722-01
DTXSID7048249 ,
SCHEMBL9260276
IVVNZDGDKPTYHK-UHFFFAOYSA-N
HMS3402J03
OPERA_ID_1844
AB00052442_06
AB00052442_05
AKOS025394868
SR-01000075340-1
sr-01000075340
CHEBI:91706
n-cyano-n'-(4-pyridyl)-n''-(1,2,2-trimethylpropyl)guanidine
sr-05000001757
SR-05000001757-2
SR-05000001757-1
bdbm50103517
SR-01000075340-3
SBI-0051008.P004
HMS3712B14
SW197742-2
DB06762
(z)-2-cyano-1-(3,3-dimethylbutan-2-yl)-3-(pyridin-4-yl)guanidine
Q821869
BRD-A43882281-001-11-4
SDCCGSBI-0051008.P005
NCGC00025188-10
p-1134;s-1230
NCGC00015787-09
MS-23474
HY-14290
EN300-6486825
n''-cyano-n'-(3,3-dimethylbutan-2-yl)-n-(pyridin-4-yl)guanidine
(z)-n'-cyano-n-(3,3-dimethylbutan-2-yl)-n''-(pyridin-4-yl)guanidine
EN300-28265907
CS-0003257
n'-cyano-n''-(3,3-dimethylbutan-2-yl)-n-(pyridin-4-yl)guanidine
F77807
AKOS040734857
c02dg01
guanidine, n''-cyano-n-4-pyridinyl-n'-(1,2,2-trimethylpropyl)-, monohydrate, (+/-)
pinacidil (mart.)
dtxcid2028224
pinacidilum (inn-latin)
MLS002153255
MLS001148221
HMS3394C13
pindac
pinacidil monohydrate, powder
cas-85371-64-8
pinacidil hydrate
pindac (tn)
pinacidil (usan)
D05482
85371-64-8
MLS001424146
smr000466919
pinacidil monohydrate
guanidine, n'-cyano-n-4-pyridinyl-n'-(1,2,2-trimethylpropyl)-, monohydrate, (+-)-
guanidine, n-cyano-n'-4-pyridinyl-n'-(1,2,2-trimethylpropyl)-, monohydrate, (+-)-
guanidine, n-cyano-n'-4-pyridinyl-n''-(1,2,2-trimethylpropyl)-, monohydrate, (+-)-
pinacidil [usan:inn]
HMS2052C13
chebi:34923 ,
CHEMBL1200338
7b0zzh8p2w ,
tox21_110954
dtxcid2025682
dtxsid4045682 ,
HMS2232E13
CCG-101112
AKOS015902794
guanidine,n-cyano-n'-4-pyridinyl-n''-(1,2,2-trimethylpropyl)-, hydrate (1:1)
pinacidil [jan]
pinacidil [vandf]
pinacidil [orange book]
pinacidil monohydrate [mi]
pinacidil monohydrate [who-dd]
pinacidil [mart.]
guanidine, n-cyano-n'-4-pyridinyl-n''-(1,2,2-trimethylpropyl)-, hydrate (1:1)
pinacidil [usan]
guanidine, n''-cyano-n-4-pyridinyl-n'-(1,2,2-trimethylpropyl)-, monohydrate, (+/-)-
SCHEMBL65786
NC00362
NCGC00263652-01
tox21_110954_1
1-cyano-3-(4-pyridyl)-2-(1,2,2-trimethylpropyl)guanidine
SCHEMBL8478960
AC-22547
Z1617901125
(+/-)-n-cyano-n'-4-pyridinyl-n''-(1,2,2-trimethylpropyl) guanidine monohydrate
n'-cyano-n''-(3,3-dimethylbutan-2-yl)-n-(pyridin-4-yl)guanidine hydrate
(e)-2-cyano-1-(3,3-dimethylbutan-2-yl)-3-(pyridin-4-yl)guanidine hydrate
AFJCNBBHEVLGCZ-UHFFFAOYSA-N
pinacidil (monohydrate)
CS-0013128
HY-14290A
1-cyano-2-(3,3-dimethylbutan-2-yl)-3-pyridin-4-ylguanidine;hydrate
AS-16742
pinacidil monohydrate (pinacidil hydrate)
(+/-)-n-cyano-n'-4-pyridinyl-n′-(1,2,2-trimethylpropyl)guanidine monohydrate
pinacidilhydrate
EN300-127030
n''-cyano-n'-(3,3-dimethylbutan-2-yl)-n-(pyridin-4-yl)guanidine hydrate
EN300-28336721
(z)-n'-cyano-n-(3,3-dimethylbutan-2-yl)-n''-(pyridin-4-yl)guanidine hydrate
AKOS040734847

Research Excerpts

Overview

Pinacidil is an effective inhibitor of hyperreflexia in the in vivo rabbit model. Pinacidil acts via direct relaxation of vascular smooth muscle to produce peripheral vasodilatation and a reduction in blood pressure.

ExcerptReferenceRelevance
"Pinacidil is a new vasodilating compound claimed to increase renal perfusion and function. "( Pinacidil--effects on function and perfusion of normal kidneys and renal xenografts.
Dieperink, H; Jørgensen, KA; Kemp, E; Starklint, H, 1983
)
3.15
"Pinacidil is a promising new antihypertensive vasodilator, which deserves further clinical evaluation."( Pinacidil, a new vasodilator, in the treatment of patients with moderate to severe hypertension.
Karatzas, NB; Koliopoulos, K; Papadoyannis, DE, 1984
)
2.43
"(1) Pinacidil is an effective inhibitor of hyperreflexia in the in vivo rabbit model."( Effect of pinacidil on spontaneous and evoked contractile activity.
Hayes, L; Levin, RM; Wein, AJ; Zhao, Y, 1992
)
1.17
"Pinacidil is a member of the new antihypertensive drug family possessing an action that involves an increased potassium efflux in vascular and cardiac muscle. "( Reperfusion-induced arrhythmias and myocardial ion shifts: a pharmacologic interaction between pinacidil and cicletanine in isolated rat hearts.
Das, DK; Szerdahelyi, P; Tosaki, A,
)
1.79
"Pinacidil is an antihypertensive agent that has been found to increase potassium conductance. "( Pinacidil opens ATP-dependent K+ channels in cardiac myocytes in an ATP- and temperature-dependent manner.
Chinn, K; Martin, CL, 1990
)
3.16
"Pinacidil is a new antihypertensive vasodilator drug which is supposed to act by opening of ATP-sensitive and glibenclamide-sensitive K+ channels in vascular smooth muscle cell membranes. "( Lack of effect of the vasodilator pinacidil on insulin secretion in healthy humans.
Mellemkjaer, S; Nielsen, CB; Nielsen-Kudsk, JE; Siggaard, C, 1990
)
2
"Pinacidil is an orally administered antihypertensive drug that acts via direct relaxation of vascular smooth muscle to produce peripheral vasodilatation and a reduction in blood pressure without significant direct effects on cardiac electrophysiology. "( Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.
Brogden, RN; Friedel, HA, 1990
)
3.16
"Pinacidil is a novel, clinically effective vasodilator used for the treatment of hypertension whose mechanism of action has not been precisely defined. "( Effects of pinacidil on serotonin-induced contractions and cyclic nucleotide levels in isolated rat aortae: comparison with nitroglycerin, minoxidil, and hydralazine.
Cohen, ML; Conery, BG; Kauffman, RF; Schenck, KW,
)
1.96
"Pinacidil is a potent antihypertensive agent in animals and humans. "( Pinacidil-induced vascular relaxation: comparison to other vasodilators and to classical mechanisms of vasodilation.
Cohen, ML; Kurz, KD, 1988
)
3.16
"Pinacidil is a potassium channel opener that decreases blood pressure by reducing peripheral arterial resistance. "( Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension.
DeSante, KA; Goldberg, MR; Rockhold, FW; Thompson, WL, 1989
)
2.01
"Pinacidil is a recently developed antihypertensive agent classified as a K+ channel opener, and is believed to depress smooth muscle activity by this action."( The action of pinacidil in the isolated human bladder.
Andersson, KE; Fovaeus, M; Hedlund, H, 1989
)
1.36
"Pinacidil is an effective vasodilator classified as a K+ channel opener."( Effects of pinacidil on bladder muscle.
Andersson, KE; Andersson, PO; Fovaeus, M; Hedlund, H; Malmgren, A; Sjögren, C, 1988
)
1.39
"Pinacidil is a new antihypertensive, direct vasodilator drug which has been classified as a K+ channel opener. "( Effects of pinacidil on guinea-pig airway smooth muscle contracted by asthma mediators.
Mellemkjaer, S; Nielsen, CB; Nielsen-Kudsk, JE; Siggaard, C, 1988
)
2.11
"Pinacidil is a newly developed antihypertensive vasodilator, proposed to belong to the new group of smooth muscle relaxants, the K+ channel openers. "( Vasodilatation with pinacidil. Mode of action in rat resistance vessels.
Aalkjaer, C; Mulvany, MJ; Videbaek, LM, 1988
)
2.04
"Pinacidil is a direct vasodilator with good absorption, a half-life of 2 to 4 hours, and side effects similar to those of other vasodilators. "( A double-blind, randomized, controlled trial comparing pinacidil to hydralazine in essential hypertension.
Byyny, RL; LoVerde, ME; Mitchell, WD; Nies, AS, 1987
)
1.96
"Pinacidil is an investigational vasodilator currently undergoing clinical trials as an antihypertensive agent. "( Effect of cirrhosis and debrisoquin phenotype on the disposition and effects of pinacidil.
Avant, GR; Hamilton, M; Patel, J; Shaheen, O; Wood, AJ, 1986
)
1.94
"Pinacidil is an arterial vasodilator currently undergoing clinical trials."( Inhibition of platelet aggregation and thromboxane production by pinacidil.
Goodman, RP; Little, DM; Wright, JT, 1985
)
1.23
"Pinacidil is an effective and well tolerated agent in the treatment of essential hypertension."( Pinacidil, a new vasodilator, in the treatment of mild to moderate essential hypertension.
D'Arcy, V; Hickey, MP; Laher, M; McCoy, D; Sullivan, P; Walsh, CH, 1985
)
2.43
"Pinacidil is a new and potent vasodilator, which has recently been used in the treatment of various forms of hypertension. "( Pharmacokinetics and bioavailability of pinacidil capsules in human volunteers.
Hickey, MP; Laher, MS, 1985
)
1.98

Effects

Pinacidil has been used for many years as a vasodilator drug to treat hypertension and its manufacture and traceability are well defined. Pinacidil solutions have been shown to have significant cardioprotective effects.

ExcerptReferenceRelevance
"Pinacidil has an asymmetrical carbon atom in the pinacolyl radical and the (-) enantiomer is more active than the (+) enantiomer both in vitro and in vivo."( Pinacidil. Preclinical investigations.
Ahnfelt-Rønne, I, 1988
)
2.44
"Pinacidil has been used for many years as a vasodilator drug to treat hypertension and its manufacture and traceability are well defined."( Pinacidil enhances survival of cryopreserved human embryonic stem cells.
Andrews, PW; Baker, D; Barbaric, I; Buchner, K; Jones, M; Moore, HD, 2011
)
2.53
"Pinacidil solutions have been shown to have significant cardioprotective effects. "( Donor heart preservation with pinacidil: the role of the mitochondrial K ATP channel.
Damiano, RJ; Diodato, MD; Gaynor, SL; Lawton, JS; Prasad, SM; Shah, NR, 2004
)
2.05
"Pinacidil has been shown to inhibit Insulin release in vitro in isolated pancreatic beta cells."( No deterioration of insulin secretion by the potassium channel opener pinacidil in essential hypertension.
Leenaers, AD; Ligtenberg, JJ; Reitsma, WD; Sluiter, WJ; Smit, AJ; Van Haeften, TW, 1996
)
1.25
"Pinacidil has an asymmetrical carbon atom in the pinacolyl radical and the (-) enantiomer is more active than the (+) enantiomer both in vitro and in vivo."( Pinacidil. Preclinical investigations.
Ahnfelt-Rønne, I, 1988
)
2.44

Actions

Pinacidil was found to inhibit aldosterone production, both basally and during stimulation with either potassium, angiotensin II (Ang II), or adrenocorticotropic hormone (p less than 0.001) Pinacidil is thought to cause vasodilatation by opening K+ channels and consequent hyperpolarization.

ExcerptReferenceRelevance
"Pinacidil was unable to activate the KATP channel in the absence of internal ATP and could even reduce channel opening in situations where activity was high in the control."( Pharmacological properties of ATP-sensitive K+ channels in mammalian skeletal muscle cells.
Allard, B; Lazdunski, M, 1993
)
1.01
"Pinacidil-induced increase in the TNS-evoked tritium overflow was still observed in the presence of cocaine or hydrocortisone."( Differential effects of diazoxide, cromakalim and pinacidil on adrenergic neurotransmission and 86Rb+ efflux in rat brain cortical slices.
Kato, H; Shimada, F; Takata, Y, 1992
)
1.26
"Pinacidil was found to inhibit aldosterone production, both basally and during stimulation with either potassium, angiotensin II (Ang II), or adrenocorticotropic hormone (p less than 0.001), with half maximal inhibition occurring at 10(-5) M."( Inhibition of aldosterone production by pinacidil in vitro.
Dominguez, JH; Pratt, JH; Rothrock, JK, 1991
)
1.27
"Pinacidil is thought to cause vasodilatation by opening K+ channels and consequent hyperpolarization. "( Effect of pinacidil on ion permeability in resting and contracted resistance vessels.
Aalkjaer, C; Hughes, AD; Mulvany, MJ; Videbaek, LM, 1990
)
2.12
"Pinacidil could also produce maximal relaxation in RMA and RAO remained unaffected in 145 mM K+ (zero Na+) depolarizing solution suggesting a lack of dependence on Na(+)-Ca++ exchange mechanism for this action of pinacidil."( Characterization of K+ channel-dependent as well as -independent components of pinacidil-induced vasodilation.
Cipkus-Dubray, LA; Khan, SA; Meisheri, KD; Oleynek, JJ; Purohit, SS; Swirtz, MA, 1991
)
1.23
"Pinacidil does not produce vasodilation via an indirect effect mediated by adenosine, prostaglandin, or endothelial-derived relaxant factor (EDRF) release."( Pinacidil-induced vascular relaxation: comparison to other vasodilators and to classical mechanisms of vasodilation.
Cohen, ML; Kurz, KD, 1988
)
2.44

Treatment

Pinacidil treatment increased ischemia-induced abbreviation of endo- and epicardial action potential durations and effective refractory periods. Treatment with pinacidil decreased APD (26%) in co-cultures with sMI-Fb.

ExcerptReferenceRelevance
"Pinacidil pretreated cardiomyocytes retained a significantly higher viability than the untreated cardiomyocytes after 90 minutes of ischemia."( A study of the relationship between pharmacologic preconditioning and adenosine triphosphate-sensitive potassium (KATP) channels on cultured cardiomyocytes using the microelectrode array.
Chan, M; Ingebrandt, S; Law, JK; Rudd, JA; Yeung, CK; Yiu, KL, 2010
)
1.08
"Pinacidil pretreatment significantly improved shock-induced decrease of vascular reactivity of superior mesenteric artery, which was antagonized by the PKCα antagonist Gö-6976 (5 × 10 mole/L) and PKCε pseudosubstrate inhibitory peptide (1 × 10 mole/L)."( Pinacidil pretreatment improves vascular reactivity after shock through PKCα and PKCε in rats.
Li, T; Liu, L; Xu, J; Yang, G, 2012
)
2.54
"Pinacidil-treated hearts had significantly better recovery of left ventricular developed pressure (47 +/- 3.8 mmHg vs 32 +/- 2.5 mmHg, P < 0.05), contractility (+dP/dt(max); 885.4 +/- 74 mmHg vs 643.7 +/- 65 mmHg, P < 0.05), left ventricular end diastolic pressure (10.5 +/- 0.9 mmHg vs 17.4 +/- 1.2 mmHg P < 0.05), compliance (-dP/dt(max); 994.2 +/- 86 mmHg vs 673.6 +/- 69 mmHg, P < 0.05), and CF (5.9 +/- 0.4 ml/min vs 4.2 +/- 0.2 ml/min, P < 0.05) compared to ischemic control. "( K(ATP) channel opener protects neonatal rabbit heart better than St. Thomas' solution.
Feng, J; Li, H; Rosenkranz, ER, 2003
)
1.76
"Pinacidil pretreatment provided superior recovery of systolic performance compared to St. "( K(ATP) channel opener protects neonatal rabbit heart better than St. Thomas' solution.
Feng, J; Li, H; Rosenkranz, ER, 2003
)
1.76
"Pinacidil pretreatment induced VF (12 of 14; p = 0.004 versus control)."( Risk of ventricular proarrhythmia with selective opening of the myocardial sarcolemmal versus mitochondrial ATP-gated potassium channel.
Barrett, TD; Fischbach, PS; Lucchesi, BR; White, A, 2004
)
1.04
"Pinacidil pretreatment increased ischemia-induced abbreviation of endo- and epicardial action potential durations and effective refractory periods."( Pretreatment with pinacidil promotes arrhythmias in an isolated tissue model of cardiac ischemia and reperfusion.
Ferrier, GR; Howlett, SE, 2005
)
1.38
"Pinacidil treatment also increased Kir6.1 protein as detected using an antibody to Kir6.1."( Channel activators regulate ATP-sensitive potassium channel (KIR6.1) expression in chick cardiomyocytes.
Halvorsen, SW; Lu, C, 1997
)
1.02
"Pinacidil pretreatment resulted in significantly fewer total ventricular ectopic beats (168 +/- 157 versus 582 +/- 448, p less than 0.005) and episodes of ventricular tachycardia (four of nine versus nine of nine, p = 0.057)."( Suppression of repolarization-related arrhythmias in vitro and in vivo by low-dose potassium channel activators.
Fish, FA; Prakash, C; Roden, DM, 1990
)
1
"Treatment with pinacidil decreased APD (26%) in co-cultures with sMI-Fb."( Fibroblast KATP currents modulate myocyte electrophysiology in infarcted hearts.
Benamer, N; Coetzee, WA; Mahoney, VM; Morley, GE; Steinhardt, MJ; Vasquez, C, 2013
)
0.73
"Pretreatment with pinacidil or levamisole significantly suppressed the elevation of reactive oxygen species (ROS) triggered by glutamate through stabilising mitochondrial membrane potential and subsequently protected HT22 cells against glutamate-induced death."( Pinacidil and levamisole prevent glutamate-induced death of hippocampal neuronal cells through reducing ROS production.
Abu El-Magd, M; Ali, R; Almadaly, E; Farrag, F; Kamal, T; Saleh, AA; Shukry, M, 2015
)
2.18
"Treatment of pinacidil, an ATP-sensitive K(+) channel opener, in the ICC using the current clamping mode, produced hyperpolarization of the membrane potential and decreased the amplitude of the pacemaker potentials."( Action of imipramine on activated ATP-sensitive K(+) channels in interstitial cells of Cajal from murine small intestine.
Choi, S; Jun, JY; Kim, JH; Kim, KW; Kim, MY; Lim, GH; Park, CG; So, I; Yeum, CH; Yoon, PJ, 2006
)
0.69
"Pretreatment with pinacidil (10(-6) to 10(-4) M) caused concentration-dependent inhibition of the contractile response to hypoxia."( Inhibition of hypoxic coronary vasoconstriction by pinacidil.
O'Rourke, ST, 1996
)
0.87
"Pretreatment with pinacidil (10(-4) M) or lemakalim (10(-5) M) inhibited the pressor response to hypoxia, but did not inhibit the response to angiotensin II."( [Effect of potassium channel openers on hypoxic pulmonary vasoconstriction].
Akiba, Y; Matsumoto, H; Nakano, H; Onodera, S; Osanai, S; Tobise, K, 1992
)
0.61
"Pretreatment with pinacidil caused a parallel shift of the tracheal histamine C/E curve to the right, whereas the maximal response to histamine was markedly depressed in the pulmonary artery."( A comparison of the relaxant effects of pinacidil in guinea-pig trachea, aorta and pulmonary artery.
Mellemkjaer, S; Nielsen, CB; Nielsen-Kudsk, JE; Siggaard, C, 1989
)
0.87

Toxicity

We compared antihypertensive effects of monotherapy with pinacidil or prazosin in a randomized, parallel, double-blind dose-titration study. hydrochlorothiazide or propranolol could be added for adverse events or lack of efficacy. Further investigation indicated that pre-treatment of pinacidill or nimodipine reversed toxic effect of MnCl(2) significantly.

ExcerptReferenceRelevance
"We compared antihypertensive effects of monotherapy with pinacidil (N = 197) or prazosin (N = 204) in a randomized, parallel, double-blind dose-titration study in which hydrochlorothiazide or propranolol could be added for adverse events or lack of efficacy."( Vasodilator monotherapy in the treatment of hypertension: comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin.
Goldberg, MR; Rockhold, FW; Sushak, CS; Thompson, WL, 1988
)
0.74
" Further investigation indicated that pre-treatment of pinacidil or nimodipine reversed toxic effect of MnCl(2) significantly."( Excitotoxicity in rat's brain induced by exposure of manganese and neuroprotective effects of pinacidil and nimodipine.
Deng, X; Deng, Y; Gao, J; Tian, Y; Xin, X; Xu, B; Xu, Z, 2009
)
0.82
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Pharmacokinetics

The peak concentration of pinacidil and N-oxide and the area under the concentration-time curve (AUC) were proportional to the dose. Pinacidil serum distribution half-life (T1/2 alpha) was 13. There were no significant changes in theophylline plasma clearance, terminal half- life or volume of distribution duringPinacidil administration.

ExcerptReferenceRelevance
" There were no significant changes in theophylline plasma clearance, terminal half-life or volume of distribution during pinacidil administration."( Lack of effect of pinacidil on theophylline pharmacokinetics and metabolism in man.
Mellemkjaer, S; Nielsen, CB; Nielsen-Kudsk, JE; Siggaard, C, 1990
)
0.82
" The peak concentration of pinacidil and N-oxide and the area under the concentration-time curve (AUC) were proportional to the dose of pinacidil, with an average pinacidil concentration of 268 micrograms/L (1."( Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension.
DeSante, KA; Goldberg, MR; Rockhold, FW; Thompson, WL, 1989
)
0.87
" In this study pharmacokinetic parameters were determined following administration of intravenous (0."( Pharmacokinetics and bioavailability of pinacidil capsules in human volunteers.
Hickey, MP; Laher, MS, 1985
)
0.54
" Pinacidil serum distribution half-life (T1/2 alpha) was 13."( Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.
Farrow, PR; McBurney, A; Sharp, P; Ward, JW, 1984
)
1.42
" Pharmacokinetic and pharmacodynamic investigations showed a tendency towards a more gradual and longer lasting antihypertensive effect and serum concentration-time curve after the retarded tablet than the previous tablet."( Pinacidil, a new vasodilator: pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension.
Carlsen, JE; Jensen, HA; Kardel, T; Tangø, M; Trap-Jensen, J, 1983
)
1.71
" The half-life was about 1 and 2 h in the two species, respectively."( Pharmacokinetics and distribution of the new antihypertensive agent pinacidil in rat, dog and man.
Arrigoni-Martelli, E; Eilertsen, E; Hart, JW; Magnussen, MP; Sørensen, H, 1982
)
0.5
" The pharmacokinetic model was incorporated into a combined pharmacokinetic-dynamic model (PK-PD) using the Hill equation, which has three parameters: n, the sigmoidicity parameter, Emax the maximum effect and EC50 the concentration which gives 50% of Emax."( Pharmacodynamic model of the haemodynamic effects of pinacidil in normotensive volunteers.
Boissel, JP; Dubois, F; Girard, P; Saumet, JL, 1993
)
0.54
" The main model-independent pharmacokinetic parameters of Pinacidil (Cmax, Tmax, AUC, MRT) as well as the absorption and the elimination half-lives were similar after the two formulations."( Pharmacodynamics and pharmacokinetics of pinacidil after a single dose of a new slow release tablet in healthy volunteers.
Bareggi, SR; Benvenuti, C; Gambaro, V; Valenti, M, 1998
)
0.81
" The main model-independent pharmacokinetic parameters of pinacidil (Cmax, Tmax, AUC, MRT), as well as the absorption and elimination half-lives were similar with the two formulations."( Pharmacodynamics and pharmacokinetics of pinacidil in normotensive volunteers after repeated doses of a new slow-release tablet formulation.
Bareggi, SR; Benvenuti, C; Gambaro, V; Valenti, M, 1999
)
0.81

Bioavailability

The effects of a standard breakfast meal on the bioavailability of a sustained-release tablet formulation of pinacidil were investigated in eight healthy volunteers. The mean bioavailability was 57% +/- 16 S.

ExcerptReferenceRelevance
"The effects of a standard breakfast meal on the bioavailability of a sustained-release tablet formulation of pinacidil [(+/-)-2-cyano-1- (4-pyridyl)-3-(1,2,2-trimethylpropyl)guanidine monohydrate) were investigated in eight healthy volunteers."( Effects of food on the bioavailability of sustained-release pinacidil in humans.
Farrow, PR; McBurney, A; Ward, JW, 1988
)
0.73
" There was no significant difference in bioavailability between the formulations, as measured by the area under the concentration-time curve (AUC0-8 h; 279 +/- 99 versus 311 +/- 85 ng."( Effects of formulation on the pharmacokinetics of orally administered pinacidil in humans.
Farrow, PR; McBurney, A; Ward, JW, 1987
)
0.51
" Mean bioavailability of pinacidil was 57."( Serum concentrations and urinary excretion of pinacidil and its major metabolite, pinacidil pyridine-N-oxide following i.v. and oral administration in healthy volunteers.
Ainsworth, S; Farrow, PR; McBurney, A; Ward, JW, 1985
)
0.83
" A bioavailability of 80% of unchanged pinacidil in the rat suggests a first-pass effect in this species."( Pharmacokinetics and distribution of the new antihypertensive agent pinacidil in rat, dog and man.
Arrigoni-Martelli, E; Eilertsen, E; Hart, JW; Magnussen, MP; Sørensen, H, 1982
)
0.77
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Pinacidil (N''-cyano-N-4-pyridyls-N'-1,2,2-trimethyl-propyl guanidine, monohydrate) is a recently developed direct-acting vasodilator. The results suggest that pinacidil at the dosage given is not effective for treatment of unstable detrusor contractions.

ExcerptRelevanceReference
" The results suggest that pinacidil at the dosage given is not effective for treatment of unstable detrusor contractions associated with bladder outflow obstruction."( Effects of pinacidil on detrusor instability in men with bladder outlet obstruction.
Andersson, KE; Hedlund, H; Mattiasson, A, 1991
)
0.97
"5 mM), glyburide (1 microM) and 20 mM K+ all caused a rightward shift of the pinacidil dose-response curve (DRC) and a corresponding increase in the pinacidil IC50."( Characterization of K+ channel-dependent as well as -independent components of pinacidil-induced vasodilation.
Cipkus-Dubray, LA; Khan, SA; Meisheri, KD; Oleynek, JJ; Purohit, SS; Swirtz, MA, 1991
)
0.74
" Consequently, the dose-response relationship of ATP inhibition was shifted to the right, but the shift approached a limiting value as pinacidil concentration was increased."( Multiple actions of pinacidil on adenosine triphosphate-sensitive potassium channels in guinea-pig ventricular myocytes.
Fan, Z; Hiraoka, M; Nakayama, K, 1990
)
0.81
" The dose-response curve of pinacidil at different [ATP]i showed a shift to the right and a depression of the maximum response at increased [ATP]i."( Interrelation between pinacidil and intracellular ATP concentrations on activation of the ATP-sensitive K+ current in guinea pig ventricular myocytes.
Fan, Z; Hiraoka, M; Marumo, F; Nakayama, K, 1990
)
0.89
" The dosage of pinacidil was 12."( Lack of effect of pinacidil on theophylline pharmacokinetics and metabolism in man.
Mellemkjaer, S; Nielsen, CB; Nielsen-Kudsk, JE; Siggaard, C, 1990
)
0.97
" During maintenance therapy with pinacidil, the average blood pressure during the daytime dosing interval was 137."( Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channels.
Goldberg, MR, 1988
)
0.86
"After dosage titration from the age of 1 month to the age of 3 months, spontaneously hypertensive rats (SHR) were treated with pinacidil 10 mg/kg daily until the age of 6 or 12 months."( Aggressive long-term antihypertensive therapy with pinacidil does not cause regression of cardiovascular hypertrophy in the spontaneously hypertensive rat.
Baandrup, U; Jespersen, LT; Lederballe, O; Mikkelsen, EO; Nyborg, NC, 1986
)
0.73
"5mg bid, respectively, with significant attenuation of these effects at both hydrochlorothiazide dosage levels."( Pinacidil with and without hydrochlorothiazide. Dose-response relationships from results of a 4 x 3 factorial design study.
Goldberg, MR; Offen, WW, 1988
)
1.72
" Daily dosage was 40-100 mg, given in two or three divided doses."( Pinacidil monotherapy for hypertension.
Ward, JW, 1984
)
1.71
"5 microM) had no significant effect on relaxation dose-response curves (DRCs) to ACh, NTG or NO."( Role of calcium-activated K+ channels in vasodilation induced by nitroglycerine, acetylcholine and nitric oxide.
Khan, SA; Mathews, WR; Meisheri, KD, 1993
)
0.29
" The dose-response curve of aortic flow to the pinacidil concentrations was flat from 5 to 50 mumol/L."( Effect of pinacidil on rat hearts undergoing hypothermic cardioplegia.
Hosoda, H; Sunamori, M; Suzuki, A, 1994
)
0.95
" The dose-response relation between ATP and the UDP-induced KATP-channel activity was shifted to the right in the presence of Mg2+ (2 mM)."( Regulation of ATP-sensitive K+ channels by ATP and nucleotide diphosphate in rabbit portal vein.
Kamouchi, M; Kitamura, K, 1994
)
0.29
" Using the simulation, it was possible to suggest an optimal dosage regimen for pinacidil tablets."( Pharmacodynamic model of the haemodynamic effects of pinacidil in normotensive volunteers.
Boissel, JP; Dubois, F; Girard, P; Saumet, JL, 1993
)
0.76
" To determine the responsiveness of coronary resistance vessels to KATP stimulation and NO, dose-response curves (DRC) for KATP opener, pinacidil-, and NO-donor, 3-morpholino-syndomine-hydrochloride (SIN-1)-induced increase in coronary flow were constructed, respectively."( Inhibitors of nitric oxide synthesis and ischemia/reperfusion attenuate coronary vasodilator response to pinacidil in isolated rat heart.
Beresewicz, A; Maczewski, M, 1997
)
0.71
" The main advantage of the tablet formulation compared to the capsules is that tablets can be easily cut and therefore the dosage can be adapted to an individual patient's needs."( Pharmacodynamics and pharmacokinetics of pinacidil after a single dose of a new slow release tablet in healthy volunteers.
Bareggi, SR; Benvenuti, C; Gambaro, V; Valenti, M, 1998
)
0.57
" One advantage of the new formulation as compared to the capsules is that the tablets can be cut easily and the dosage adapted to a patient's needs."( Pharmacodynamics and pharmacokinetics of pinacidil in normotensive volunteers after repeated doses of a new slow-release tablet formulation.
Bareggi, SR; Benvenuti, C; Gambaro, V; Valenti, M, 1999
)
0.57
"1) Pinacidil dose-dependently decreased gastric tone at a dosage of 30 (p = 0."( Roles of ATP sensitive potassium channel in modulating gastric tone and accommodation in dogs.
Chen, JD; Lei, Y; Li, S, 2017
)
1.08
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (55)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency6.30960.044717.8581100.0000AID485294
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.35480.044717.8581100.0000AID485294
glp-1 receptor, partialHomo sapiens (human)Potency14.12540.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency1.37510.100020.879379.4328AID588453
GLS proteinHomo sapiens (human)Potency17.78280.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency16.10450.000811.382244.6684AID686978; AID686979
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency35.48130.011212.4002100.0000AID1030
alpha-galactosidaseHomo sapiens (human)Potency3.16234.466818.391635.4813AID2107
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency18.16950.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency3.54810.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency95.283423.934123.934123.9341AID1967
chromobox protein homolog 1Homo sapiens (human)Potency28.18380.006026.168889.1251AID488953
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency1.83560.00419.984825.9290AID504444
VprHuman immunodeficiency virus 1Potency12.58931.584919.626463.0957AID651644
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency3.16230.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency1.99530.177824.735279.4328AID488949
lamin isoform A-delta10Homo sapiens (human)Potency1.25890.891312.067628.1838AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency5.01190.015812.3113615.5000AID1461
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency35.48130.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency100.00003.981146.7448112.2020AID720708
GABA theta subunitRattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
TDP1 proteinHomo sapiens (human)Potency29.47410.000811.382244.6684AID686978; AID686979
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.94970.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency6.00700.000214.376460.0339AID720691
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency23.71010.001530.607315,848.9004AID1224849
GVesicular stomatitis virusPotency3.89020.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency21.87610.00108.379861.1304AID1645840
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency23.71010.001723.839378.1014AID743083
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624297
Interferon betaHomo sapiens (human)Potency3.89020.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency3.89020.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency5.30800.002319.595674.0614AID651631
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency3.89020.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency3.89020.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Muscarinic acetylcholine receptor M1Mus musculus (house mouse)IC50 (µMol)8.90000.00333.21788.9000AID141403
Muscarinic acetylcholine receptor M4Mus musculus (house mouse)IC50 (µMol)8.90000.00333.21788.9000AID141403
Muscarinic acetylcholine receptor M5Mus musculus (house mouse)IC50 (µMol)8.90000.00333.21788.9000AID141403
Muscarinic acetylcholine receptor M3Mus musculus (house mouse)IC50 (µMol)8.90000.00333.21788.9000AID141403
Muscarinic acetylcholine receptor M2Mus musculus (house mouse)IC50 (µMol)8.90000.00333.22478.9000AID141403
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)221.60000.40002.75008.6000AID1209456
Bile salt export pumpHomo sapiens (human)IC50 (µMol)254.70000.11007.190310.0000AID1209455; AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 9Homo sapiens (human)EC50 (µMol)3.54000.02190.70193.5400AID347643
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (212)

Processvia Protein(s)Taxonomy
defense response to virusATP-binding cassette sub-family C member 9Homo sapiens (human)
action potentialATP-binding cassette sub-family C member 9Homo sapiens (human)
heart morphogenesisATP-binding cassette sub-family C member 9Homo sapiens (human)
response to xenobiotic stimulusATP-binding cassette sub-family C member 9Homo sapiens (human)
response to ATPATP-binding cassette sub-family C member 9Homo sapiens (human)
negative regulation of blood pressureATP-binding cassette sub-family C member 9Homo sapiens (human)
fibroblast proliferationATP-binding cassette sub-family C member 9Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 9Homo sapiens (human)
coronary vasculature developmentATP-binding cassette sub-family C member 9Homo sapiens (human)
cardiac conductionATP-binding cassette sub-family C member 9Homo sapiens (human)
potassium ion transmembrane transportATP-binding cassette sub-family C member 9Homo sapiens (human)
cardiac muscle cell contractionATP-binding cassette sub-family C member 9Homo sapiens (human)
monoatomic cation transmembrane transportATP-binding cassette sub-family C member 9Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 9Homo sapiens (human)
inorganic cation transmembrane transportATP-binding cassette sub-family C member 9Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 9Homo sapiens (human)
potassium ion import across plasma membraneATP-binding cassette sub-family C member 9Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (71)

Processvia Protein(s)Taxonomy
monoatomic cation channel activityATP-binding cassette sub-family C member 9Homo sapiens (human)
potassium channel activityATP-binding cassette sub-family C member 9Homo sapiens (human)
ATP-activated inward rectifier potassium channel activityATP-binding cassette sub-family C member 9Homo sapiens (human)
transmembrane transporter activityATP-binding cassette sub-family C member 9Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 9Homo sapiens (human)
sulfonylurea receptor activityATP-binding cassette sub-family C member 9Homo sapiens (human)
potassium channel regulator activityATP-binding cassette sub-family C member 9Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 9Homo sapiens (human)
ATPase-coupled monoatomic cation transmembrane transporter activityATP-binding cassette sub-family C member 9Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 9Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 9Homo sapiens (human)
transmembrane transporter bindingATP-binding cassette sub-family C member 9Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 9Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (47)

Processvia Protein(s)Taxonomy
plasma membraneMuscarinic acetylcholine receptor M3Mus musculus (house mouse)
plasma membraneATP-binding cassette sub-family C member 9Homo sapiens (human)
sarcomereATP-binding cassette sub-family C member 9Homo sapiens (human)
inward rectifying potassium channelATP-binding cassette sub-family C member 9Homo sapiens (human)
potassium ion-transporting ATPase complexATP-binding cassette sub-family C member 9Homo sapiens (human)
membraneATP-binding cassette sub-family C member 9Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (268)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID141403Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to muscarinic receptor in mice1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Synthesis and biological evaluation of [125I]- and [123I]-4-iododexetimide, a potent muscarinic cholinergic receptor antagonist.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID181490Systolic blood pressure was measured at intervals from 1 to 6 hr in groups of six rats after oral administration of a dose of 3 mg/kg1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and antihypertensive activity of 4-(substituted-carbonylamino)-2H-1-benzopyrans.
AID194545Compound is evaluated for the effect on Oxytocin-Induced contractions of rat uterus at 10 uM2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID666762Myorelaxant effect in oxytoxin-induced Wistar rat uterus smooth muscle assessed as residual contractile activity by continuous superfusion of oxytocin at 100 uM2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and pharmacological activity of N-(2,2-dimethyl-3,4-dihydro-2H-1-benzopyran-4-yl)-4H-1,2,4-benzothiadiazine-3-carboxamides 1,1-dioxides on rat uterus, rat aorta and rat pancreatic β-cells.
AID233236Estimated selectivity ratio of ED50 and IC50 in rat was calculated2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID181489Systolic blood pressure was measured at intervals from 1 to 6 hr in groups of six rats after oral administration of a dose of 1 mg/kg1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and antihypertensive activity of 4-(substituted-carbonylamino)-2H-1-benzopyrans.
AID596281Myorelaxant effect in Wistar rat uterus smooth muscle assessed as inhibition of contractions induced by continuous superfusion of oxytocin in presence of 10 uM ATP-sensitive potassium channel blocker glibenclamide2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Impact of the nature of the substituent at the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides on their opening activity toward ATP-sensitive potassium channels.
AID1148611Toxicity in rat assessed as effect on contraction of nictitating membranes by preganglionic stimulation1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID383536Inhibition of electrical field stimulation-induced neurogenic contractions in New Zealand white rabbit gastric fundus smooth muscle2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Evaluation of myorelaxant activity of 7-substituted hexahydroquinoline derivatives in isolated rabbit gastric fundus.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID195733Percentage residual insulin secretion at 1 uM dose from pancreatic islets incubated in the presence of 16.7 mM glucose2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID1148551Toxicity in po dosed Sprague-Dawley rat assessed as mortality after 7 days1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID194548Compound is evaluated for the effect on Oxytocin-Induced contractions of rat uterus at 50 uM2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID195743Percent inhibition of residual insulin release from rat pancreatic islets in the presence of 16.7 mM glucose at 10 uM concentration2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID20831Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the excretion of sodium at 5 mg/kg concentration1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel potassium-channel openers: preparation and pharmacological evaluation of racemic and optically active N-(6-amino-3-pyridyl)-N'-bicycloalkyl-N"-cyanoguanidine derivatives.
AID247010Myorelaxant activity of the compound against insulin secretion in the pancreatic islets ofrat; (activity expressed as ED50)2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
4,6-Disubstituted 2,2-dimethylchromans structurally related to the K(ATP) channel opener cromakalim: design, synthesis, and effect on insulin release and vascular tone.
AID247873Inhibitory concentration against rat vascular smooth muscle tissue2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
4,6-Disubstituted 2,2-dimethylchromans structurally related to the K(ATP) channel opener cromakalim: design, synthesis, and effect on insulin release and vascular tone.
AID226482Hill Coefficient calculated by curve fitting of data to a single binding site model1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Binding of ATP-sensitive potassium channel (KATP) openers to cardiac membranes: correlation of binding affinities with cardioprotective and smooth muscle relaxing potencies.
AID195200Myorelaxant activity in rat aorta with 10 uM glibenclamide and 30 mM KCL2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID407862Ratio of IC50 for inhibition of glucose-induced insulin secretion in Wistar rat pancreatic beta islets to ED50 for myorelaxant activity in Wistar rat aortic rings2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Synthesis and activity on rat aorta rings and rat pancreatic beta-cells of ring-opened analogues of benzopyran-type potassium channel activators.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID452149Channel opening activity at KATP channel in Wistar rat pancreatic islets assessed as glucose-induced residual insulin secretion at 1 uM after 90 mins by radioimmunology2009Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22
New R/S-3,4-dihydro-2,2-dimethyl-2H-1-benzopyrans as K(ATP) channel openers: modulation of the 4-position.
AID1148597Vasodilatory activity in conscious normotensive dog assessed as change in heart rate at 0.5 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID195734Percentage residual insulin secretion at 10 uM dose from pancreatic islets incubated in the presence of 16.7 mM glucose2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID1148560Hypotensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as maximum change in mean blood pressure at 1 mg/kg, po relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148561Hypotensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as time required for persistence of hypotensive effect at 2.5 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID177639Effect on contractile activity of 30 mM potassium-Depolarized rat aorta incubated in the presence of 10 uM Glibenclamide2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID347647Selectivity ratio of EC50 for mouse SUR1/Kir6.2 potassium ATP channel to human SUR2B/Kir6.2 potassium ATP channel2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery and structure-activity relationships of a novel series of benzopyran-based K(ATP) openers for urge urinary incontinence.
AID195191Relaxation of phenylephrine precontracted rat isolated aorta rings.2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Arylcyanoguanidines as activators of Kir6.2/SUR1K ATP channels and inhibitors of insulin release.
AID195199Myorelaxant activity in rat aorta with 1 uM glibenclamide and 30 mM KCL2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID596291Myorelaxant effect in Wistar rat uterus smooth muscle assessed as inhibition of contractions induced by bolus of oxytocin injected in superfusion system at 50 uM2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Impact of the nature of the substituent at the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides on their opening activity toward ATP-sensitive potassium channels.
AID1294397Inhibition of glucose-induced insulin secretion from Wistar rat pancreatic islets assessed as residual insulin release at 1 uM after 90 mins by radioimmunological assay2016European journal of medicinal chemistry, Jun-10, Volume: 115Synthesis, characterization and biological evaluation of benzothiazoles and tetrahydrobenzothiazoles bearing urea or thiourea moieties as vasorelaxants and inhibitors of the insulin releasing process.
AID1148568Hypotensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as time required for persistence of hypotensive effect at 0.5 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID222118Compound was tested for relaxant activity in trachea for asthma in male guinea pigs1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
Biologically selective potassium channel openers having 1,1-diethylpropyl group.
AID20833Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the excretion of sodium at vehicle concentration1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel potassium-channel openers: preparation and pharmacological evaluation of racemic and optically active N-(6-amino-3-pyridyl)-N'-bicycloalkyl-N"-cyanoguanidine derivatives.
AID347643Channel opening activity at SUR2B/Kir6.2 potassium ATP channel in human TE671 cells assessed as isometric force by FLIPR2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery and structure-activity relationships of a novel series of benzopyran-based K(ATP) openers for urge urinary incontinence.
AID383534Myorelaxant activity against noradrenaline-induced contractions in New Zealand white rabbit gastric fundus smooth muscle2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Evaluation of myorelaxant activity of 7-substituted hexahydroquinoline derivatives in isolated rabbit gastric fundus.
AID452150Channel opening activity at KATP channel in Wistar rat endothelium-denuded aortic ring assessed as relaxation of KCl-induced contraction2009Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22
New R/S-3,4-dihydro-2,2-dimethyl-2H-1-benzopyrans as K(ATP) channel openers: modulation of the 4-position.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID180316Inhibitory concentration against methoxamine-induced contractions in rat aorta1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Binding of ATP-sensitive potassium channel (KATP) openers to cardiac membranes: correlation of binding affinities with cardioprotective and smooth muscle relaxing potencies.
AID1148550Hypotensive activity in po dosed spontaneously hypertensive Wistar-Okamoto rat assessed as dose required to cause 30 mmHg fall of blood pressure administered for 5 days1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID196958Myorelaxant activity as percentage residual contractile activity in rat uterus at 50 uM concentration.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID195735In vitro percentage residual insulin secretion at 50 uM dose from rat pancreatic islets incubated in the presence of 16.7 mM glucose.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID384245Ratio of IC50 for glucose-induced insulin secretion in Wistar rat pancreatic beta islets to EC50 for myorelaxant activity in Wistar rat aorta rings2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
New R/S-3,4-dihydro-2,2-dimethyl-6-halo-4-(phenylaminothiocarbonylamino)-2H-1-benzopyrans structurally related to (+/-)-cromakalim as tissue-selective pancreatic beta-cell K(ATP) channel openers.
AID20830Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the excretion of sodium at 1 mg/kg concentration1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel potassium-channel openers: preparation and pharmacological evaluation of racemic and optically active N-(6-amino-3-pyridyl)-N'-bicycloalkyl-N"-cyanoguanidine derivatives.
AID195359Effective dose required for relaxation of the 30 mM KCl-induced contraction of rat aortic rings2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID383535Myorelaxant activity against noradrenaline-induced contractions in New Zealand white rabbit gastric fundus smooth muscle in presence of glibenclamide2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Evaluation of myorelaxant activity of 7-substituted hexahydroquinoline derivatives in isolated rabbit gastric fundus.
AID195201In vitro inhibition of 30 mM KCl-induced contraction of rat aorta rings.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID1148588Hypotensive activity in po dosed spontaneously hypertensive Wistar-Okamoto rat relative to hydralazine1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1072508Myorelaxant activity in New Zealand white rabbit gastric fundus smooth muscle assessed as relaxation of noradrenaline-induced contraction2014European journal of medicinal chemistry, Mar-21, Volume: 75Microwave-assisted synthesis and myorelaxant activity of 9-indolyl-1,8-acridinedione derivatives.
AID176359Concentration giving 50% relaxation of the 30 mM KCL-induced contraction of rat aorta rings2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID166322Increase in rubidium-86 efflux in rabbit isolated mesenteric artery over basal rate1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and antihypertensive activity of 4-(substituted-carbonylamino)-2H-1-benzopyrans.
AID407859Activation of ATP-sensitive potassium channel in Wistar rat pancreatic beta islets assessed as glucose-induced residual insulin secretion at 50 uM relative to control2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Synthesis and activity on rat aorta rings and rat pancreatic beta-cells of ring-opened analogues of benzopyran-type potassium channel activators.
AID1148593Vasodilatory activity in conscious normotensive dog assessed as change in blood pressure at 0.5 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID17056Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel potassium-channel openers: preparation and pharmacological evaluation of racemic and optically active N-(6-amino-3-pyridyl)-N'-bicycloalkyl-N"-cyanoguanidine derivatives.
AID667956Growth inhibition of human U373 cells after 72 hrs by MTT assay2012European journal of medicinal chemistry, Aug, Volume: 54N-Aryl-N'-(chroman-4-yl)ureas and thioureas display in vitro anticancer activity and selectivity on apoptosis-resistant glioblastoma cells: screening, synthesis of simplified derivatives, and structure-activity relationship analysis.
AID407861Activation of ATP-sensitive potassium channel in potassium-depolarized Wistar rat aortic rings assessed as myorelaxant activity against KCl-induced contraction2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Synthesis and activity on rat aorta rings and rat pancreatic beta-cells of ring-opened analogues of benzopyran-type potassium channel activators.
AID179236Compound was tested for vasorelaxant activity on the basis of ability to relax endothelium-denuded rat aortic strips toned with 20 mM KCl1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel potassium-channel openers: preparation and pharmacological evaluation of racemic and optically active N-(6-amino-3-pyridyl)-N'-bicycloalkyl-N"-cyanoguanidine derivatives.
AID177641Effect on contractile activity of 80 mM potassium-Depolarized rat aorta2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID1148601Vasodilatory activity in conscious normotensive dog assessed as cardiac output at 0.5 mg/kg, po by thermodilution method1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID666760Myorelaxant effect in oxytoxin-induced Wistar rat uterus smooth muscle assessed as residual contractile activity by continuous superfusion of oxytocin at 10 uM2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and pharmacological activity of N-(2,2-dimethyl-3,4-dihydro-2H-1-benzopyran-4-yl)-4H-1,2,4-benzothiadiazine-3-carboxamides 1,1-dioxides on rat uterus, rat aorta and rat pancreatic β-cells.
AID347649Vasorelaxant activity in rat bladder assessed as inhibition of carbachol-induced contraction2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery and structure-activity relationships of a novel series of benzopyran-based K(ATP) openers for urge urinary incontinence.
AID384242Inhibition of glucose-induced insulin secretion in Wistar rat pancreatic beta islets assessed as residual insulin secretion at 1 uM relative to control2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
New R/S-3,4-dihydro-2,2-dimethyl-6-halo-4-(phenylaminothiocarbonylamino)-2H-1-benzopyrans structurally related to (+/-)-cromakalim as tissue-selective pancreatic beta-cell K(ATP) channel openers.
AID190149The hypotensive activity expressed as rating of therapeutic index (MED/LD50 <1/200).1980Journal of medicinal chemistry, Jan, Volume: 23, Issue:1
Adaptive least-squares method applied to structure--activity correlation of hypotensive N-alkyl-N''-cyano-N'-pyridylguanidines.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID48985Binding affinity was determined by displacement of [3H]P1075 from its binding sites in canine cardiac membranes1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Binding of ATP-sensitive potassium channel (KATP) openers to cardiac membranes: correlation of binding affinities with cardioprotective and smooth muscle relaxing potencies.
AID1148549Toxicity in po dosed mouse assessed as mortality after 7 days1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148578Hypotensive activity in conscious renal hypertensive dog assessed as maximum change in mean blood pressure at 1 mg/kg, po measured for 8 hrs relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1294393Vasorelaxant activity in Wistar rat thoracic aortic rings assessed relaxation of 30 mM KCl-induced contraction in presence of KATP channel blocker glibenclamide2016European journal of medicinal chemistry, Jun-10, Volume: 115Synthesis, characterization and biological evaluation of benzothiazoles and tetrahydrobenzothiazoles bearing urea or thiourea moieties as vasorelaxants and inhibitors of the insulin releasing process.
AID222119Compound was tested for relaxant activity in urinary bladder for urinary incontinence in male guinea pigs1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
Biologically selective potassium channel openers having 1,1-diethylpropyl group.
AID1148587Hypotensive activity in conscious renal hypertensive dog assessed as time required for persistence of hypotensive effect at 1 mg/kg, po measured for 8 hrs1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID596288Inhibition of glucose induced insulin secretion from rat Pancreatic islet assessed as percentage of residual insulin release2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Impact of the nature of the substituent at the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides on their opening activity toward ATP-sensitive potassium channels.
AID596292Myorelaxant effect in Wistar rat uterus smooth muscle assessed as inhibition of contractions induced by bolus of oxytocin injected in superfusion system at 10 uM2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Impact of the nature of the substituent at the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides on their opening activity toward ATP-sensitive potassium channels.
AID1148585Hypotensive activity in conscious renal hypertensive dog assessed as time required for persistence of hypotensive effect at 0.5 mg/kg, po measured for 8 hrs1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID193411Maximum percent fall in Systolic blood pressure (SBP) was measured in anesthetized normotensive rat for 30 mins after intravenous (iv) injection at 0.3 mg/kg dose1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Novel potassium channel openers: synthesis and pharmacological evaluation of new N-(substituted-3-pyridyl)-N'-alkylthioureas and related compounds.
AID190860Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the urinary volume at 1 mg/kg concentration1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel potassium-channel openers: preparation and pharmacological evaluation of racemic and optically active N-(6-amino-3-pyridyl)-N'-bicycloalkyl-N"-cyanoguanidine derivatives.
AID347646Channel opening activity at SUR2A/Kir6.2 potassium ATP channel in african green monkey COS7 cells assessed as isometric force by FLIPR2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery and structure-activity relationships of a novel series of benzopyran-based K(ATP) openers for urge urinary incontinence.
AID596290Myorelaxant effect in Wistar rat uterus smooth muscle assessed as inhibition of contractions induced by bolus of oxytocin injected in superfusion system at 100 uM2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Impact of the nature of the substituent at the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides on their opening activity toward ATP-sensitive potassium channels.
AID58754The compound was tested for its antihypertensive activity in dogs after intravenous injection2000Bioorganic & medicinal chemistry letters, Nov-06, Volume: 10, Issue:21
NMR analysis of tautomerisms of active pinacidil-type potassium channel openers and a less active one.
AID1148559Hypotensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as maximum change in mean blood pressure at 0.5 mg/kg, po relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID189325Insulin secretion from rat pancreatic islets (RIS) in the presence of 16.7 mM glucose at 50 uM2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625294Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID596283Myorelaxant effect in Wistar rat uterus smooth muscle assessed as inhibition of contractions induced by continuous superfusion of oxytocin in presence of 1 uM ATP-sensitive potassium channel blocker glibenclamide2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Impact of the nature of the substituent at the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides on their opening activity toward ATP-sensitive potassium channels.
AID177640Effect on contractile activity of 30 mM potassium-Depolarized rat aorta incubated in the presence of 1 uM Glibenclamide2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1148584Hypotensive activity in conscious renal hypertensive dog assessed as time required for persistence of hypotensive effect at 0.25 mg/kg, po measured for 8 hrs1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID407860Activation of ATP-sensitive potassium channel in Wistar rat pancreatic beta islets assessed as glucose-induced residual insulin secretion at 10 uM relative to control2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Synthesis and activity on rat aorta rings and rat pancreatic beta-cells of ring-opened analogues of benzopyran-type potassium channel activators.
AID1294392Vasorelaxant activity in Wistar rat endothelium-denuded thoracic aortic rings assessed relaxation of 30 mM KCl-induced contraction2016European journal of medicinal chemistry, Jun-10, Volume: 115Synthesis, characterization and biological evaluation of benzothiazoles and tetrahydrobenzothiazoles bearing urea or thiourea moieties as vasorelaxants and inhibitors of the insulin releasing process.
AID437030Cardioprotective effect in Langendorff perfused isolated rat hearts assessed as reduction in ischemic injury2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Predictive models, based on classification algorithms, for compounds potentially active as mitochondrial ATP-sensitive potassium channel openers.
AID197347Concentration required to cause 15% increase in [86Rb+] efflux from rat portal vein.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Structure-activity studies of potassium channel opening in pinacidil-type cyanoguanidines, nitroethenediamines, thioureas, and ureas.
AID667966Cell cycle arrest in human U373 cells assessed as accumulation at G0/G1 phase at 30 to 100 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis2012European journal of medicinal chemistry, Aug, Volume: 54N-Aryl-N'-(chroman-4-yl)ureas and thioureas display in vitro anticancer activity and selectivity on apoptosis-resistant glioblastoma cells: screening, synthesis of simplified derivatives, and structure-activity relationship analysis.
AID161275Binding affinity towards potassium channel of rat aorta using [3H]15 as radioligand1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
Synthesis of and radioligand binding studies with a tritiated pinacidil analogue: receptor interactions of structurally different classes of potassium channel openers and blockers.
AID197345Negative logarithm of the concentration causing a 100% inhibition of spontaneous mechanical activity in rat portal vein is determined in vitro1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Novel potassium channel openers: synthesis and pharmacological evaluation of new N-(substituted-3-pyridyl)-N'-alkylthioureas and related compounds.
AID596289Myorelaxant effect in KCl-induced precontracted rat aorta ring VSMC2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Impact of the nature of the substituent at the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides on their opening activity toward ATP-sensitive potassium channels.
AID1148552Hypotensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as maximum change in mean blood pressure at 2.5 mg/kg, po relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID179405Concentration required to inhibit insulin release in rat2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID1148608Toxicity in rat assessed as change in cardiac noradrenaline level at 1 mg/kg1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID452148Channel opening activity at KATP channel in Wistar rat pancreatic islets assessed as glucose-induced residual insulin secretion at 10 uM after 90 mins by radioimmunology2009Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22
New R/S-3,4-dihydro-2,2-dimethyl-2H-1-benzopyrans as K(ATP) channel openers: modulation of the 4-position.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID231686Ratio between Na+ and K+ excretion values at a dose of 5 mg/kg1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel potassium-channel openers: preparation and pharmacological evaluation of racemic and optically active N-(6-amino-3-pyridyl)-N'-bicycloalkyl-N"-cyanoguanidine derivatives.
AID1148576Hypotensive activity in conscious renal hypertensive dog assessed as maximum change in mean blood pressure at 0.5 mg/kg, po measured for 8 hrs relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148605Vasodilatory activity in conscious normotensive dog assessed as total peripheral resistance at 0.5 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID384244Myorelaxant activity in potassium depolarized Wistar rat aorta rings assessed as relaxation of KCl-induced contraction2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
New R/S-3,4-dihydro-2,2-dimethyl-6-halo-4-(phenylaminothiocarbonylamino)-2H-1-benzopyrans structurally related to (+/-)-cromakalim as tissue-selective pancreatic beta-cell K(ATP) channel openers.
AID384243Inhibition of glucose-induced insulin secretion in Wistar rat pancreatic beta islets assessed as residual insulin secretion relative to control2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
New R/S-3,4-dihydro-2,2-dimethyl-6-halo-4-(phenylaminothiocarbonylamino)-2H-1-benzopyrans structurally related to (+/-)-cromakalim as tissue-selective pancreatic beta-cell K(ATP) channel openers.
AID196957Myorelaxant activity as percentage residual contractile activity in rat uterus at 10 uM concentration.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID228165Vasorelaxant activity expressed as negative logarithm of the concentration causing a 50% inhibition of spontaneous myogenic activity in rat portal vein.1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
Synthesis of and radioligand binding studies with a tritiated pinacidil analogue: receptor interactions of structurally different classes of potassium channel openers and blockers.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID217610Inhibition of [3H]-P1075 binding to ATP-sensitive potassium channels of rat cardiac membranes1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Vasorelaxation by new hybrid compounds containing dihydropyridine and pinacidil-like moieties.
AID231685Ratio between Na+ and K+ excretion values at a dose of 1 mg/kg1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel potassium-channel openers: preparation and pharmacological evaluation of racemic and optically active N-(6-amino-3-pyridyl)-N'-bicycloalkyl-N"-cyanoguanidine derivatives.
AID1148575Hypotensive activity in conscious renal hypertensive dog assessed as maximum change in mean blood pressure at 0.25 mg/kg, po measured for 8 hrs relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID177031Compound was tested for hypotensive activity in anesthetized normotensive rats by intravenous injection. Systolic blood pressure measured 30 min after injection1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel potassium-channel openers: preparation and pharmacological evaluation of racemic and optically active N-(6-amino-3-pyridyl)-N'-bicycloalkyl-N"-cyanoguanidine derivatives.
AID1148590Hypotensive activity in decerebrated cat1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID79039In vitro inhibition electrically stimulated guinea pig ileum segment contraction.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID195198Myorelaxant activity in rat aorta in the presence 80 mM KCL.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID77612Intrinsic activity measured on Guinea pig tracheal spiral strips.1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Relaxant activity of 4-amido-3,4-dihydro-2H-1-benzopyran-3-ols and 4-amido-2H-1-benzopyrans on guinea pig isolated trachealis.
AID212401Compound was tested for relaxant activity in taenia caecum1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
Biologically selective potassium channel openers having 1,1-diethylpropyl group.
AID195744Percent inhibition of residual insulin release from rat pancreatic islets in the presence of 16.7 mM glucose at 50 uM concentration2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID195738Inhibition of residual insulin release from rat pancreatic islets in the presence of 16.7 mM glucose at 0.1 uM concentration; Not determined2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID44711In vitro ability to inhibit glucose stimulated insulin release in beta-TC6 cells from rat islets2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Arylcyanoguanidines as activators of Kir6.2/SUR1K ATP channels and inhibitors of insulin release.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID194546Compound is evaluated for the effect on Oxytocin-Induced contractions of rat uterus at 100 uM2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID347648Selectivity ratio of EC50 for african green monkey SUR2A/Kir6.2 potassium ATP channel to human SUR2B/Kir6.2 potassium ATP channel2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery and structure-activity relationships of a novel series of benzopyran-based K(ATP) openers for urge urinary incontinence.
AID44577Ability to repolarize beta-TC3 cell membrane potential; Not significant2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Arylcyanoguanidines as activators of Kir6.2/SUR1K ATP channels and inhibitors of insulin release.
AID220538Compound was tested for antihypertensive activity in dogs by intravenous injection at a dose 30 ug/kg1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
Biologically selective potassium channel openers having 1,1-diethylpropyl group.
AID29374Ionisation constant (pKa1) due to protonation of the pyridyl ring1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Structure-activity studies of potassium channel opening in pinacidil-type cyanoguanidines, nitroethenediamines, thioureas, and ureas.
AID1294395Inhibition of glucose-induced insulin secretion from Wistar rat pancreatic islets assessed as residual insulin release at 50 uM after 90 mins by radioimmunological assay2016European journal of medicinal chemistry, Jun-10, Volume: 115Synthesis, characterization and biological evaluation of benzothiazoles and tetrahydrobenzothiazoles bearing urea or thiourea moieties as vasorelaxants and inhibitors of the insulin releasing process.
AID666758Inhibition of glucose-induced insulin secretion from Wistar rat pancreatic islet assessed as residual insulin release at 50 uM after 90 mins by radiometric analysis2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and pharmacological activity of N-(2,2-dimethyl-3,4-dihydro-2H-1-benzopyran-4-yl)-4H-1,2,4-benzothiadiazine-3-carboxamides 1,1-dioxides on rat uterus, rat aorta and rat pancreatic β-cells.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID384241Inhibition of glucose-induced insulin secretion in Wistar rat pancreatic beta islets assessed as residual insulin secretion at 10 uM relative to control2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
New R/S-3,4-dihydro-2,2-dimethyl-6-halo-4-(phenylaminothiocarbonylamino)-2H-1-benzopyrans structurally related to (+/-)-cromakalim as tissue-selective pancreatic beta-cell K(ATP) channel openers.
AID596280Myorelaxant effect in Wistar rat uterus smooth muscle assessed as inhibition of contractions induced by continuous superfusion of oxytocin in absence ATP-sensitive potassium channel blocker glibenclamide2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Impact of the nature of the substituent at the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides on their opening activity toward ATP-sensitive potassium channels.
AID17055Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel potassium-channel openers: preparation and pharmacological evaluation of racemic and optically active N-(6-amino-3-pyridyl)-N'-bicycloalkyl-N"-cyanoguanidine derivatives.
AID253017Percentage of residual insulin secretion value in the pancreatic islets of rat after treatment with the compound at 10 uM concentration2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
4,6-Disubstituted 2,2-dimethylchromans structurally related to the K(ATP) channel opener cromakalim: design, synthesis, and effect on insulin release and vascular tone.
AID1072509Myorelaxant activity in New Zealand white rabbit gastric fundus smooth muscle assessed as relaxation of noradrenaline-induced contraction at 3 x 10'-4 M relative to control2014European journal of medicinal chemistry, Mar-21, Volume: 75Microwave-assisted synthesis and myorelaxant activity of 9-indolyl-1,8-acridinedione derivatives.
AID190862Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the urinary volume at vehicle concentration1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel potassium-channel openers: preparation and pharmacological evaluation of racemic and optically active N-(6-amino-3-pyridyl)-N'-bicycloalkyl-N"-cyanoguanidine derivatives.
AID29396Ionisation constant (pKa2) due to proton loss from the pyridine ring1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Structure-activity studies of potassium channel opening in pinacidil-type cyanoguanidines, nitroethenediamines, thioureas, and ureas.
AID666761Myorelaxant effect in oxytoxin-induced Wistar rat uterus smooth muscle assessed as residual contractile activity by continuous superfusion of oxytocin at 50 uM2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and pharmacological activity of N-(2,2-dimethyl-3,4-dihydro-2H-1-benzopyran-4-yl)-4H-1,2,4-benzothiadiazine-3-carboxamides 1,1-dioxides on rat uterus, rat aorta and rat pancreatic β-cells.
AID1294396Inhibition of glucose-induced insulin secretion from Wistar rat pancreatic islets assessed as residual insulin release at 10 uM after 90 mins by radioimmunological assay2016European journal of medicinal chemistry, Jun-10, Volume: 115Synthesis, characterization and biological evaluation of benzothiazoles and tetrahydrobenzothiazoles bearing urea or thiourea moieties as vasorelaxants and inhibitors of the insulin releasing process.
AID347645Channel opening activity at SUR1/Kir6.2 potassium ATP channel in mouse beta-TC6 cells assessed as isometric force by FLIPR2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery and structure-activity relationships of a novel series of benzopyran-based K(ATP) openers for urge urinary incontinence.
AID17054Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel potassium-channel openers: preparation and pharmacological evaluation of racemic and optically active N-(6-amino-3-pyridyl)-N'-bicycloalkyl-N"-cyanoguanidine derivatives.
AID1148569Hypotensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as time required for persistence of hypotensive effect at 1 mg/kg, po1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID195192In vitro ability to relax phenylephrine contracted rat aorta rings2001Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13
Phenylcyanoguanidines as inhibitors of glucose-induced insulin secretion from beta cells.
AID383537Reversal of inhibition of electrical field stimulation-induced neurogenic contractions in New Zealand white rabbit gastric fundus smooth muscle in presence of glibenclamide2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Evaluation of myorelaxant activity of 7-substituted hexahydroquinoline derivatives in isolated rabbit gastric fundus.
AID195742Percent inhibition of residual insulin release from rat pancreatic islets in the presence of 16.7 mM glucose at 1 uM concentration2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID177638Effect on contractile activity of 30 mM potassium-Depolarized rat aorta incubated in the absence of Glibenclamide2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID1148610Toxicity in rat assessed as change in cardiac noradrenaline level at 1 mg/kg for 5 days1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID179774In vitro inhibitory concentration that relaxes KCL induced contraction in rat detrusor strips by 50%2000Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6
Design and SAR of novel potassium channel openers targeted for urge urinary incontinence. 1. N-Cyanoguanidine bioisosteres possessing in vivo bladder selectivity.
AID197525Concentration required to cause 50% inhibition of spontaneous activity in rat portal vein1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Structure-activity studies of potassium channel opening in pinacidil-type cyanoguanidines, nitroethenediamines, thioureas, and ureas.
AID189324Effect on Insulin secretion from rat pancreatic islets (RIS) in the presence of 16.7 mM glucose at 10 uM2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID175306Effective concentration required to increase time to the onset of contracture (TTC) in globally ischemic rat hearts1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Binding of ATP-sensitive potassium channel (KATP) openers to cardiac membranes: correlation of binding affinities with cardioprotective and smooth muscle relaxing potencies.
AID1294391Vasorelaxant activity in Wistar rat endothelium-intact thoracic aortic rings assessed relaxation of 30 mM KCl-induced contraction2016European journal of medicinal chemistry, Jun-10, Volume: 115Synthesis, characterization and biological evaluation of benzothiazoles and tetrahydrobenzothiazoles bearing urea or thiourea moieties as vasorelaxants and inhibitors of the insulin releasing process.
AID190861Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the urinary volume at 5 mg/kg concentration1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel potassium-channel openers: preparation and pharmacological evaluation of racemic and optically active N-(6-amino-3-pyridyl)-N'-bicycloalkyl-N"-cyanoguanidine derivatives.
AID76811Inhibition of electrically stimulated contractions of guinea pig ileum segments.2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID1294394Vasorelaxant activity in Wistar rat thoracic aortic rings assessed relaxation of 80 mM KCl-induced contraction2016European journal of medicinal chemistry, Jun-10, Volume: 115Synthesis, characterization and biological evaluation of benzothiazoles and tetrahydrobenzothiazoles bearing urea or thiourea moieties as vasorelaxants and inhibitors of the insulin releasing process.
AID193410Maximum percent fall in Systolic blood pressure (SBP) was measured in anesthetized normotensive rat for 30 mins after intravenous (iv) injection at 0.1 mg/kg dose1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Novel potassium channel openers: synthesis and pharmacological evaluation of new N-(substituted-3-pyridyl)-N'-alkylthioureas and related compounds.
AID76393Inhibition of spontaneous tone in Guinea pig tracheal spiral strips.1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Relaxant activity of 4-amido-3,4-dihydro-2H-1-benzopyran-3-ols and 4-amido-2H-1-benzopyrans on guinea pig isolated trachealis.
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID44710In vitro efficacy to inhibit glucose stimulated insulin release in beta-TC6 cells from rat islets; No data2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Arylcyanoguanidines as activators of Kir6.2/SUR1K ATP channels and inhibitors of insulin release.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346630Rat Kir6.2 (Inwardly rectifying potassium channels)1996The Journal of biological chemistry, Oct-04, Volume: 271, Issue:40
A novel sulfonylurea receptor forms with BIR (Kir6.2) a smooth muscle type ATP-sensitive K+ channel.
AID1346573Mouse Kir6.2 (Inwardly rectifying potassium channels)1996Neuron, May, Volume: 16, Issue:5
A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels.
AID1346625Mouse Kir6.1 (Inwardly rectifying potassium channels)1997The Journal of physiology, Mar-15, Volume: 499 ( Pt 3)Sulphonylurea receptor 2B and Kir6.1 form a sulphonylurea-sensitive but ATP-insensitive K+ channel.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,031)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990128 (12.42)18.7374
1990's422 (40.93)18.2507
2000's321 (31.13)29.6817
2010's145 (14.06)24.3611
2020's15 (1.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.46 (24.57)
Research Supply Index7.00 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index53.29 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials41 (3.87%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews27 (2.55%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
Other991 (93.58%)84.16%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]